How do payment delays affect a TB patient in real terms?
TB patients need nutritious meals; undernutrition weakens immune responses and slows recovery from disease.
For patients undergoing long TB treatment regimens spread over months, poor nutrition can also make it harder to adhere to medication schedules, or even complete the therapy.
The first few weeks of treatment are the most critical. If nutritional support is delayed, patients may struggle to afford adequate food, feel weaker and less able to continue treatment, and skip doses or drop out altogether.
In practical terms, a delay means the support arrives after the period when it could have prevented treatment interruption, so its benefit is reduced or even lost.
Where is the biggest gap between policy and implementation?
The main gap is that the policy assumes support is delivered promptly, but in reality, payments are often delayed or not received.
So while coverage looks high on paper, effective coverage (timely receipt) is lower.
Fixing it would require the government to track timeliness, not just the number of beneficiaries. It would also mean that the government would need to automate payments with fewer approval steps and monitor delays in real time through digital systems.
Are some groups more affected than others?
While the model is not stratified, real-world evidence suggests a higher risk among economically vulnerable patients, rural or remote populations, patients in weaker health systems and those without stable bank access.
Interventions should prioritise high-burden districts, socially vulnerable populations and patients at high risk of loss to follow-up.
What indicators should officials track?
Instead of only tracking coverage, programmes should monitor percentage of patients receiving first payment within a defined time window (timeliness), average delay in payment (days/weeks), effective coverage (received + timely payments), treatment success rate, loss to follow-up, and deaths during treatment.
The key shift required is from “how many have been paid” to “how quickly the money is paid”.
How much improvement is possible by fixing timelines?
Our model shows that just improving timeliness (without increasing coverage) can lead to about 5–8 percentage point increase in treatment success, around 5–7 percentage point reduction in loss to follow up, and around two to three per cent reduction in TB mortality at the population level. This is a substantial gain from an operational fix alone.
Which is worse: delays or incomplete coverage?
Both matter, but the model suggests that delays are often the bigger problem in practice. This is because though the coverage may appear high on paper, if payments are delayed, real effectiveness is reduced.
A delayed payment behaves almost like no support during the critical phase.
Is ₹500 adequate? What should be prioritised?
The model does not directly evaluate the adequacy of the amount (cost-effectiveness work is in progress), but it shows even with the current amount (Rs 1000), improving timeliness produces measurable benefits.
So, the short-term priority should be to fix delivery (timeliness), while the long term priority should be to reassess the amount — Rs 1000 would be likely insufficient given inflation.
One immediate recommendation would be to ensure that the first payment is delivered early in treatment (front-loaded). Based on our findings, improvements in treatment outcomes could be seen within one or two years of intervention implementation. Population-level mortality effects would accumulate over time.
How was the model built, and what data was used?
The study employed a compartmental mathematical model to simulate tuberculosis (TB) transmission and treatment, calibrated in two distinct stages. In the first stage, representing the pre-NPY era (2012–2017), the model was fitted to baseline TB dynamics using key burden indicators such as incidence, mortality, and case notifications. In the second stage (2018–2022), the model was recalibrated to capture the effects of the NPY intervention, incorporating treatment outcomes including treatment success, loss to follow-up, and treatment-related mortality.
A key strength of the model is that it explicitly accounts for real-world implementation factors such as coverage, timeliness, and the gradual scale-up of the intervention over time. The calibration draws on multiple data sources, including WHO TB data, programmatic treatment outcomes, and previous research on intervention effects. This integrated approach allows the model to realistically represent both epidemiological trends and operational constraints.
The final takeaway is that the study shows that improving when patients receive support can be almost as important as whether they receive it. Fixing delays is one of the fastest and most practical ways to improve TB outcomes.
lakshmipriya.nair@expressindia.com
laxmipriyanair@gmail.com